Methdilazine
Mechanism :
It is an antihistaminic agent with moderate sedative properties. It also has antimuscarinic action.
Indication :
- It is used in allergic conditions such as urticaria, angioedema, rhinitis and conjunctivitis.
Dosing :
0.3 mg/kg/dose 6-8 hourly PO/IV.
Adverse Effect :
GI disturbances, headache, sedation, dizziness.
Interaction :
Bromocriptine: The phenothiazine decreases the effect of bromocriptine.
Cisapride: Increased risk of cardiotoxicity and arrhythmias.
Dexfenfluramine: Decreased anorexic effect, may increase psychotic symptoms.
Diethylpropion: Decreased anorexic effect, may increase psychotic symptoms.
Donepezil: Possible antagonism of action.
Fenfluramine: Decreased anorexic effect, may increase psychotic symptoms.
Galantamine: Possible antagonism of action.
Guanethidine: Methdilazine may decrease the effect of guanethidine.
Mazindol: Decreased anorexic effect, may increase psychotic symptoms.
Phentermine: Decreased anorexic effect, may increase psychotic symptoms.
Phenylpropanolamine: Decreased anorexic effect, may increase psychotic symptoms.
Terfenadine: Increased risk of cardiotoxicity and arrhythmias.
Hepatic Dose :
Metabolism may be decreased; higher serum concentrations may increase sensitivity to CNS effects.